DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients.
Read the press release

DiaSorin  announces the launch of a fully automated serology test to detect antibodies against Sars-CoV-2 in Covid-19 patients within the end of April 2020 
DiaSorin Molecular LLC, a division of DiaSorin S.p.A., has received the Emergency Use Authorization (EUA) from the FDA for their Simplexa™ COVID-19 Direct kit. The kit provides a sample-to-answer test for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, directly from nasopharyngeal swab specimens. Read the press release
Visit our booth #Z5.C30 and discover our new solution.
Medlab Middle East , 
Dubai World Trade Centre, 3 - 6 February 2020